|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
4/2022
vol. 97 abstract:
Case report
Romiplostim – an emergency treatment of intracranial haemorrhage in the course of severe primary immune thrombocytopaenia
Paweł Łaguna
1, 2
,
Aleksandra Sikorska
1
,
Joanna Kulik
1
,
Michał Matysiak
1, 2
Pediatr Pol 2022; 97 (4): 343-346
Online publish date: 2022/12/30
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
We present a case of a 16-year-old girl with newly diagnosed/persistent immune thrombocytopaenia (ITP) with a complication of intracranial haemorrhage. She did not respond adequately to first-line treatment, i.e. intravenous immunoglobulin infusions, glucocorticosteroids, and transfusion of platelets, and developed numerous bleeding complications. During the treatment she developed bleeding into the central nervous system, which is a rare and devastating complication of ITP. In such cases, the available data in the literature suggest a potential role of the thrombopoietin receptor agonist as a life-saving emergency treatment for severe, newly diagnosed immune thrombocytopaenia. The prognosis of our patient’s survival and neurological status was completely dependent on this treatment. After obtaining consent from the appropriate bioethics committee, romiplostim was administered to the patient, with a good response and without side effects.
keywords:
platelet count, ITP, intracranial haemorrhage, romiplostim |
POLSKI
